Tumor vessel co-option: The past & the future

Abstract

Tumor vessel co-option (VCO) is a non-angiogenic vascularization mechanism that is a possible cause of resistance to anti-angiogenic therapy (AAT). Multiple tumors are hypothesized to primarily rely on growth factor signaling-induced sprouting angiogenesis, which is often inhibited during AAT. During VCO however, tumors invade healthy tissues by hijacking pre-existing blood vessels of the host organ to secure their blood and nutrient supply. Although VCO has been described in the context of AAT resistance, the molecular mechanisms underlying this process and the profile and characteristics of co-opted vascular cell types (endothelial cells (ECs) and pericytes) remain poorly understood, resulting in the lack of therapeutic strategies to inhibit VCO (and to overcome AAT resistance). In the past few years, novel next-generation technologies (such as single-cell RNA sequencing) have emerged and revolutionized the way of analyzing and understanding cancer biology. While most studies utilizing single-cell RNA sequencing with focus on cancer vascularization have centered around ECs during sprouting angiogenesis, we propose that this and other novel technologies can be used in future investigations to shed light on tumor EC biology during VCO. In this review, we summarize the molecular mechanisms driving VCO known to date and introduce the models used to study this phenomenon to date. We highlight VCO studies that recently emerged using sequencing approaches and propose how these and other novel state-of-the-art methods can be used in the future to further explore ECs and other cell types in the VCO process and to identify potential vulnerabilities in tumors relying on VCO. A better understanding of VCO by using novel approaches could provide new answers to the many open questions, and thus pave the way to develop new strategies to control and target tumor vascularization.

Crystal ribcage: a platform for probing real-time lung function at cellular resolution in health and disease

“…To answer the long-standing questions surrounding remodeling of the structure and function of the alveoli by tumors, we investigated two mouse models of breast cancer lung metastasis with differential growth patterns. According to our previous work 16 and others’ 17 , tumor growth patterns are generally categorized as nodular (growth as a dense nodule that pushes the existing normal tissue outward) or infiltrative (cancer cells replace normal cells with minimal remodeling of surrounding architecture and blood vessels; also known as co-optive 18 ), with distinct biological and clinical outcomes. Motivated by these works, we probed the differential alterations in structure and function in nodular vs infiltrative metastatic tumors modeled by murine breast cancer cell lines MCa-M3C-H2B-dendra2 and E0771-H2B-dendra2, respectively ( Fig.…”

Basic Pathogenic Mechanisms and Epigenetic Players Promoted by Extracellular Vesicles in Vascular Damage

“…Moreover, data from EVs containing miR-92a-3p, derived from colon cancer cells, showed upregulation of mesenchymal markers, such as snail and vimentin, and downregulated the tight junction marker ZO-1 in HUVECs referred as “partial-EndoMT” [ 142 ]. EVs released from tumor cells during hypoxia participate in the EndMT switch of TECs, particularly EVs loaded with lysyl oxidase-like 2 protein (LOXL2) [ 143 ]. LOXL2 is a member of the LOX family and regulates extracellular matrix (ECM) remodeling, angiogenesis and premetastatic niche formation.…”

Research progress of ginseng in the treatment of gastrointestinal cancers

“…Invasion and migration of tumor cells are malignant behavior of tumor cells; invasion refers to the invasion or occupation of malignant tumors from the primary or secondary tumors to adjacent host tissues; metastasis refers to a recurrent multistep process in which the primary tumor spreads to distant organs. Tumor cells leave the primary tumor to invade the surrounding tissues, enter the blood or lymphatic vessels, and are transported to distant sites to recolonize in a new organ environment ( Cuypers et al, 2022 ). Tumor metastasis is an important cause of cancer treatment failure and recurrence ( Ishay-Ronen et al, 2019 ).…”